Rocket Pharmaceuticals Inc (RCKT) - News Archive

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) recently found itself at the center of a class action lawsuit initiated by the Pomerantz Law Firm. The suit targets what it describes as potential securities fraud, suggesting...

Rocket Pharmaceuticals Secures FDA RMAT Designation for Pioneering Gene Therapy Targeting PKP2-Arrhythmogenic CardiomyopathyIn a significant advancement for both Rocket Pharmaceuticals, Inc. and the realm of genetic the...

Rocket Pharmaceuticals Faces Class Action Lawsuit amidst Improved Financial Metrics Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a prominent player in the biopharmaceutical industry, is currently navigating through a ch...

In an era where genetic therapy promises revolutionary breakthroughs in treating rare diseases, Rocket Pharmaceuticals, Inc. has found itself at a pivotal junction. The firm, known for developing therapies for genetic d...

In an epoch-defining announcement, Rocket Pharmaceuticals, Inc. a leader in the biotechnology industry, has unveiled promising data from its Phase 1 clinical trial of RP-A601, aimed at treating patients with plakophilin...

Rocket Pharmaceuticals Expands Horizons: Strategic Offerings and Pivotal Trials Propel Company Forward in Genetic Therapy for Rare Disorders In a significant stride towards advancing its innovative pipeline, Rocket Phar...

: Rocket Pharmaceuticals, Inc. a leading biotechnology company, has announced significant milestones in their genetic therapy programs. The publication of long-term data in the New England Journal of Medicine and a pres...

CRANBURY, N.J. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a prominent player in the biotechnology sector, specializes in the development of innovative gene therapies aimed at treating rare diseases that currently have...

In its latest quarterly report, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) revealed its financial results for the second quarter of 2024, along with significant updates on its clinical programs focused on genetic thera...

Advancing Genetic Therapies for Rare Disorders: An In-Depth Look at Rocket Pharmaceuticals’ Second Quarter 2024 Progress and Financial Performance Rocket Pharmaceuticals, Inc., a notable entity in the late-stage biotech...

Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) Following FDA Complete Response Letter Cranbury, N.J. - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrate...

Rocket Pharmaceuticals, a late-stage biotechnology company specializing in genetic therapies for rare disorders, recently presented longer-term data updates from its lentiviral (LV) vector hematology portfolio at the 27...

Rocket Pharmaceuticals Inc. has recently made significant changes to its corporate leadership team, with the appointment of Aaron Ondrey as Chief Financial Officer (CFO). The company, a leading late-stage biotechnology...

Rocket Pharmaceuticals, a late-stage biotechnology company dedicated to developing innovative genetic therapies for rare disorders, has recently reported its financial and operational results for the fourth quarter and...

Rocket Pharmaceuticals Faces Delays in FDA Review of Promising Rare Disease TreatmentRocket Pharmaceuticals, a leading biotechnology company focused on genetic therapies for rare disorders, recently announced that the U...

IntroductionRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has emerged as a formidable player in the biotechnology industry, working relentlessly towards developing genetic therapies for rare disorders with high unmet need...